Mosby's 2014 Nursing Drug Reference (58 page)

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

beclomethasone (Rx)

(be-kloe-meth′a-sone)

QVAR

Func. class.:
Corticosteroid, synthetic

Chem. class.:
Glucocorticoid

Do not confuse:
beclomethasone
/betamethasone

ACTION:

Prevents inflammation by suppression of the migration of polymorphonuclear leukocytes, fibroblasts and the reversal of increased capillary permeability and lysosomal stabilization; does not suppress hypothalamus and pituitary function

USES:

Chronic asthma, allergic/vasomotor rhinitis, nasal polyps

CONTRAINDICATIONS:

Hypersensitivity, status asthmaticus (primary treatment)

Precautions:
Pregnancy (C), breastfeeding, children <12 yr, nasal disease/surgery, nonasthmatic bronchial disease; bacterial, fungal, viral infections of mouth, throat, lungs; HPA suppression, osteoporosis, Cushing’s syndrome, diabetes mellitus, measles, cataracts, corticosteroid hypersensitivity, glaucoma, herpes infection

DOSAGE AND ROUTES
Calculator

• Adult and child >12 yr: ORAL INH
40-80 mcg bid (alone) or 40-160 mcg bid (previous inhaled corticosteroids); max 320 mcg bid

• Child 5-11 yr: ORAL INH
40 mcg bid; max 80 mcg bid

Available forms:
Oral inh 40, 80, 250
mcg/metered spray

Administer:

• 
Bronchodilator spray; if used, should be used 1st, then wait a few minutes, then use beclomethasone

• 
Prime before 1st use or if not used for 7-10 days; prime by spraying 2 actuations into the air, away from the face; do not share inhaler

• 
Oral inhalation
(metered-dose non-CFC aerosol) (QVAR); shake well, use spacer; after using, rinse mouth, gargle if possible; clean weekly with dry cloth/tissue, do not wash inhaler

• 
Titrated dose, use lowest effective dose

SIDE EFFECTS

CNS:
Headache

EENT:
Hoarseness, candidal infection of oral cavity, sore throat
, loss of taste/smell, dysgeusia

ENDO:
HPA suppression

GI:
Dry mouth, dyspepsia

MISC:
Angioedema, adrenal insufficiency,
facial edema, Churg-Strauss syndrome (rare)

RESP:
Bronchospasm,
wheezing, cough

PHARMACOKINETICS

INH:
Onset 1-4 wk; excreted in feces, urine (metabolites); half-life 2.8 hr; crosses placenta; metabolized in lungs, liver (by CYP3A)

NURSING CONSIDERATIONS
Assess:

• 
For fungal infection in mucous membranes

• 
Adrenal function periodically for HPA axis suppression during prolonged therapy, monitor growth/development

Perform/provide:

• 
Gum, rinsing of mouth for dry mouth

Evaluate:

• 
Therapeutic response: decreased dyspnea, wheezing, dry crackles

Teach patient/family:

• 
To gargle/rinse mouth after each use to prevent oral fungal infections

• 
That during times of stress, systemic corticosteroids may be needed to prevent adrenal insufficiency; not to discontinue oral product abruptly, to taper slowly

• 
To notify prescriber if therapeutic response decreases; dosage adjustment may be needed

• 
Proper administration technique and cleaning technique

• 
About all aspects of product usage, including cushingoid symptoms

• 
About
adrenal insufficiency symptoms:
nausea, anorexia, fatigue, dizziness, dyspnea, weakness, joint pain, depression

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

beclomethasone (nasal)

(be-kloe-meth′a-sone)

Beconase AQ, Qnasal

Func. class.:
Nasal corticosteroid

ACTION:

Readily crosses cell membranes and binds with high affinity to specific cytoplasmic receptors; inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, and suppression of humoral immune responses

USES:

To relieve symptoms of seasonal/perennial rhinitis

CONTRAINDICATIONS:

Hypersensitivity

Precautions:
Child <6 yr, untreated fungal infections, glaucoma and/or cataracts, nasal septum ulcers/surgery/trauma

DOSAGE AND ROUTES
Calculator

• Adult/child ≥12 yr:
Nasal 1-2 sprays in each nostril bid (42 mcg/spray); 2 sprays in each nostril every day (80 mcg/actuation)

• Child 6-12 yr:
Nasal 1 spray in each nostril bid

Available forms:
nasal spray 42 mcg/metered spray; nasal aerosol 80 mcg/actuation

Administer

• 
Products are not always interchangeable owing to differences in route of administration and in the amount of active drug released per spray

• 
To avoid the spread of infection, do not use the container for more than one person

• 
Product’s effectiveness depends on regular use

Nasal inhalation (metered-dose aerosol) (Qnasal):

• 
Instruct patient to shake the canister well before administering

• 
Before first use, instruct the patient to prime the pump by actuating 4 times. After the initial priming, the dose-counter should read 120

• 
If the canister is not used for 7 consecutive days, instruct the patient to prime by actuating 2 times

• 
Instruct patient on proper administration technique

Nasal inhalation (pump spray) (Beconase AQ):

• 
Instruct patient to shake the nasal sprayer well before use

• 
Before first use, instruct the patient to prime the pump by actuating 6 times

• 
If the pump is not used for 7 days, prime until a fine spray appears

• 
Instruct patient on proper administration technique

• 
After use, rinse the tip of the bottle with hot water, taking care not to suck water into the bottle, and dry with a clean tissue; replace the cap

SIDE EFFECTS

CNS:
Headache, dizziness

EENT:
Nasal burning, epistaxis, nasal fungal infections, nasal congestion, sneezing

GI:
Nausea

PHARMACOKINETICS

Onset 7 days, peak 21 days, half-life 15 hr

NURSING CONSIDERATIONS
Assess:

• 
Nasal symptoms: Assess for sneezing, running of nose before and after use, avoid use longer than 3 wk, check for fungal infections, changes in vision

Evaluate:

• 
Decrease nasal running, sneezing, other symptoms of seasonal/perennial rhinitis

Teach patient/family:

• 
That products are not always interchangeable owing to differences in route of administration and in the amount of active drug released per spray

• 
To avoid the spread of infection, do not use the container for more than one person

• 
That product effectiveness depends on regular use

Nasal inhalation (metered-dose aerosol) (Qnasal):

• 
Instruct patient to shake the canister well before administering

• 
Before first use, instruct the patient to prime the pump by actuating 4 times. After the initial priming, the dose-counter should read 120

• 
If the canister is not used for 7 consecutive days, instruct the patient to prime by actuating 2 times

• 
Instruct patient on proper administration technique

Nasal inhalation (pump spray) (Beconase AQ):

• 
Instruct patient to shake the nasal sprayer well before use

• 
Before first use, instruct the patient to prime the pump by actuating 6 times

• 
If the pump is not used for 7 days, prime until a fine spray appears

• 
Instruct patient on proper administration technique

• 
After use, rinse the tip of the bottle with hot water, taking care not to suck water into the bottle, and dry with a clean tissue; replace the cap

Other books

Black Treacle Magazine (Issue 4) by Black Treacle Publications
Cows by Matthew Stokoe
Desire (#2) by Cox, Carrie
Strike Zone by Kate Angell
Juicio Final by John Katzenbach
Poetic Justice by Alicia Rasley
Dissent by Gadziala, Jessica